

Australian Government

Department of Health

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	353138	METAGENICS VEGETARIAN DIGESTIVE ENZYMES	
ARTG entry for	Medicine Listed		
Sponsor	Metagenics (Aust) Pty Ltd		
Postal Address	PO Box 675, VIF Australia	RGINIA BC, QLD, 4014	
ARTG Start Date	15/01/2021		
Product Category	Medicine		
Status	Active		
Approval Area	Listed Medicines	5	
• · · · ·			

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

Product Type	Single Medicine Product	Effective Date	19/04/2021
Permitted Indicatio	ns		
Maintain/support he	althy digestion		
Aid/assist/helps dige	estion of fats/fatty acids/triglycerides/lipid		
Ū.	of glucose/sugar/carbohydrates		
Aid/assist/helps dige	estion of (state nutrient)		
Indication Require	ments		
Product presentatio	n must not imply or refer to lowering or rais	ing blood sugar/glucose levels from	outside of the normal healthy range.
Product presentatio	n must not imply or refer to lowering blood	lipids, blood fats and triglycerides.	
Standard Indication	ns		
No Standard Indicat	ions included on Record		
Specific Indication	S		
No Specific Indication	ons included on Record		
Warnings			
If symptoms persist	consult your healthcare practitioner (or wor	ds to that effect).	
Additional Product	information		
Pack Size/Poison i	nformation		
Pack Size		Poison Schedule	
Components			
1. Formulation 1			
Dosage Form	Capsule, hard		
Route of Adminis	stration _{Oral}		
Visual Identificat	ion		
Active Ingredien	ts		
/tente ingreaten			



Australian Government

Department of Health Therapeutic Goods Administration

Amylase cellulase lipase

protease

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate colloidal anhydrous silica disodium edetate gellan gum hypromellose magnesium stearate maltodextrin microcrystalline cellulose potable water

potassium acetate

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

15 thousand DU 2 thousand CU 600 LipU 30 Thousand HUT

Public Summary

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown. Visit www.tga.gov.au for contact information

This is not an ARTG Certificate document.